Background: We sought to determine temporal trends in the receipt of prostatectomy or locoregional radiation to the prostate for patients with metastatic prostate cancer and to identify predictors of receipt of local treatment. Methods: We identified 39,976 patients with metastatic prostate cancer diagnosed in 2004e2012 using the National Cancer Database (NCDB). We used logistic multivariable regression to determine trends in the receipt of prostate and/or pelvic radiation or radical prostatectomy after adjusting for demographic and clinical factors. 
Introduction
Prostate cancer remains the second most frequently diagnosed cancer in men and the leading cause of cancer death after lung cancer. 1 With the advent of improved awareness and screening programs, more cases are diagnosed at the early stages of prostate cancer. Still, <5% of patients will present with metastasis at diagnosis, 2 and up to 40% of patients will experience recurrence of disease after conventional radical therapy. 3 Although the 5-year cause-specific survival rate for men who present without metastasis is nearly 100%, patients who present with metastasis have only 28% survival expectancy. 4 Appropriate treatment for this group of patients therefore remains an active area of interest. Current guidelines recommend immediate or deferred hormone therapy [androgen deprivation therapy (ADT)] as palliative therapy for metastatic prostate cancer. 5 This treatment modality offers improvement of disease-related symptoms, delayed tumor progression, and increased survival. 3 Recent studies suggest that the use of local treatment of the primary tumor may improve outcomes for metastatic patients. 6e11 Similar work in breast cancer, 12 colon cancer, 13 and ovarian cancer 14 has suggested a survival benefit from local surgery or radiation.
Although data supporting local treatment of metastatic prostate cancer have accumulated in recent years, the retrospective nature of these studies has limited a more widespread adoption of the treatment paradigm. We sought to assess how trends in the treatment of metastatic prostate cancer have evolved in light of the shifting evidence for and against local treatment. Reflecting on current clinical practice patterns may inform future directions for study in these challenging patients.
Materials and methods

Data acquisition
Patient information was obtained from the National Cancer Database (NCDB) after approval from the DanaeFarber/Harvard Cancer Center Institutional Review Board. The NCDB is a national oncology database overseen by the Commission on Cancer and the American Cancer Society. Collectively, the database encompasses 70% of all newly diagnosed cases of cancer in the United States. For our purposes, patients with a diagnosis of prostate cancer were selected (n ¼ 1,802,596). We used a subset of patients with metastatic disease at the time of diagnosis based on the variable coded by the Collaborative Stage Data Collection System. The study was limited to patients diagnosed after 2004, when the variable was first introduced to the database (n ¼ 39,976). Patients for whom treatment data were unavailable were excluded.
Statistical analysis
Patient information was entered into STATA software (StataCorp LP, College Station, Texas, version 14.1) for data analysis. Demographic information was calculated according to coded variables in the NCDB database. Comparison of categorical variables was made using the chi-square test, whereas continuous variables were compared with Student t test. Logistic regression was performed in STATA for the treatment modalities of interest using year of diagnosis as a covariate and controlling for potential confounding factors such as age, race, income, education level, and comorbidity level (based on CharlsoneDeyo Score). We used a two-sided P value of < 0.05 as the criterion for statistical significance.
Results
Patient demographics
Based on review, 39,976 patients with metastatic prostate cancer diagnosed from 2004 to 2012 were identified. Patients were classified as those receiving definitive locoregional treatment (surgery or radiation of the primary tumor, n ¼ 2,752) or no locoregional treatment (n ¼ 37,224). From surgical cases, we did not count as definitive any patients who received only local destruction of tumor or local excision, or subtotal prostatectomy, or unspecified surgical procedures. Population characteristics are presented in Table 1 comparing no locoregional treatment to patients receiving locoregional treatment. Notable differences included increased age, higher rates of comorbidities, and higher rates of elevated prostatespecific antigen (PSA) among patients who did not receive locoregional therapy. Patients receiving locoregional therapy were more likely to have been treated at an academic institution. (Fig. 1 ). Cofactors associated with decreased likelihood for locoregional treatment included older age (AOR ¼ 0.96, 95% CI ¼ 0.96e0.96, P < 0.001) and increased comorbidity level (1 comorbidity: AOR ¼ 0.82, 95% CI ¼ 0.73e0.93, P ¼ 0.001; 2 or more comorbidities: AOR ¼ 0.49, 95% CI ¼ 0.39e0.61, P < 0.001). Patients in the top income quartile assessed by zip code were found to be more likely to receive locoregional treatment (AOR ¼ 1.25 per year, 95% CI ¼ 1.06e1.48, P ¼ 0.007). Race, education, and income level did not otherwise predict receipt of locoregional treatment (Table 2 ).
Trends in locoregional therapy are contributed to by decreased use of both radiation and surgery
Trends in utilization of locoregional therapy were subdivided into treatment with radiation to the prostate and/or pelvis or surgery of the primary site for further analysis. Radiation therapy included the use of external beam and brachytherapy or combined modality treatment. Multivariable logistic regression again showed that patients were less likely to receive locoregional radiation (5.9% in 2004 to 4.2% in 2012, AOR ¼ 0.97 per year, 95% CI ¼ 0.95e0.99, P < 0.001) ( Table 3) . Treatment with radiation was also stratified by PSA (recorded as the highest PSA documented prior to diagnostic biopsy) to see if trends were different in patients with low PSA as a (Fig. 2) . Finally, subgroup analysis of locoregional trends was performed by stratifying over M stage. There was a decrease in the use of locoregional treatment for M1b patients (metastasis in bone ± -distant lymph nodes), but the trend was not significant for M1a (distant lymph nodes) or M1c (other distant metastasis ± bone or distant lymph nodes). In looking specifically at patients receiving radiation, there was again a decrease in treatment for M1b patients but not for M1a or M1c patients. No significant trends were found among patients undergoing surgery (Table 3) .
Trends in use of systemic therapies differ over time
Use of systemic therapy including ADT and chemotherapy was trended over time. Overall, there was no change in the use of chemotherapy in newly diagnosed metastatic patients (AOR ¼ 0.99, 95% CI 0.97e1.00, P ¼ 0.13). By comparison, use of ADT in patients with metastatic prostate cancer was higher than use of any locoregional therapy. Logistic regression for use of ADT showed a significant increase over time (70.2% in 2004 compared to 77.9% in 2012, AOR ¼ 1.05 per year, 95% CI 1.04e1.06) (Fig. 2) . Stratification of systemic therapy by M stage (as above) showed a nonsignificant increase in use of chemotherapy for M1c patients despite an overall decrease chemotherapy use and decreases in the M1a and M1b subgroups. The increase in use of ADT was composed of increases in treatment in all subgroups (M1aeM1c) ( Table 3 ).
Discussion
The objective of this study was to quantify changes in the use of locoregional treatment for metastatic prostate cancer over time. We found that the rate of locoregional treatment (radiation or surgery) given to the prostate decreased during our study period (from 7.88% to 5.53% between 2004 and 2012), and that older age and increased comorbidity on the CharlsoneDeyo score were predictors of decreased treatment. More specifically, subdivision of locoregional treatment showed that the decreasing trend was composed of decreases in both local radiation and surgery of the primary site. Stratification by M stage showed a decrease in treatment of M1b patients with locoregional therapies and a similar decrease in use of radiation for M1b patients. Changes in treatment of M1a and M1c patients along with use of surgery for oligometastatic patients were not significant. Conversely, there was an increasing trend in the use of ADT for newly diagnosed metastatic patients. This result was surprising because of the emerging data on the potential value of locoregional treatment in node positive and metastatic disease.
6e11 For example, in a review of the SEER (Surveillance, Epidemiology, and End Results)-Medicare database, Satkunasivam et al 15 showed that radical prostatectomy and intensitymodulated radiation therapy (IMRT) were associated with decreased risk of prostate cancer-specific mortality at 6 months (52% reduction and 62% reduction, respectively) relative to no local therapy for patients with metastatic prostate cancer. Additionally, Culp et al 3 showed that 5-year survival and disease-specific survival were significantly higher after radical prostatectomy (67.4% and 75.8%, respectively) or brachytherapy (52.6% and 61.3%, respectively) compared to no local treatment (22.5% and 48.7%, respectively) among men with Stage IV disease. 3 Most recently, Loppenberg et al 16 used NCDB data to demonstrate improved 3-year overall mortality-free survival rates in metastatic prostate cancer patients who were treated with local therapy compared to no local therapy (66% vs. 51%, respectively; P < 0.001). Parikh et al 17 found that among NCDB patients, 5-year overall survival was improved for patients who received local therapy compared to those who did not (45.7% vs. 17.1%, P < 0.01), although only radical prostatectomy and IMRTdbut not 2D/3D conformal radiation therapydconferred overall survival benefit compared to no local therapy. Notably, this study excluded patients who received chemotherapy who were included here to inform comparisons between local and systemic therapy use. 17 Similarly, Rusthoven et al 18 found that among metastatic prostate cancer patients treated with ADT, addition of prostate radiotherapy (RT) improved overall survival on univariate (P < 0.001) and multivariate analysis (hazard ratio ¼ 0.624, 95% CI ¼ 0.551e0.706, P < 0.001) adjusted for age, year, race, comorbidity score, PSA level, Gleason score, T stage, N stage, chemotherapy administration, treating facility, and insurance status. Despite differences in inclusion criteria (notably, exclusion of chemotherapy patients in Parikh et al's study 17 and limitation to ADT patients in Rusthoven et al's study 18 ), our paper aligns well with these NCDB studies in showing the decreasing trend in use of local therapy despite the apparent benefit. Kaplan et al 19 discuss that treatment of the primary site may be of importance in preventing further metastatic spread because of factors secreted, in addition to oncogenic cells, that promote growth in secondary sites. A supporting study showed that circulating malignant cells had decreased metastatic potential after treatment of the primary tumor. 20 Specifically, in renal cell carcinoma, two randomized trials comparing treatment of patients presenting with metastatic cancer found that systemic therapy combined with radical nephrectomy showed significant survival benefit. 21, 22 These findings lend legitimacy to the theory that locoregional treatment of the primary tumor may improve outcomes for metastatic prostate cancer. One possible explanation for the decreasing trend is that the studies focusing exclusively on local therapy for metastatic disease were published in recent years, and so there was no time for these data to be reflected in practice patterns prior to 2012. 3, 4, 15, 16 However, it should be noted that there was some evidence suggesting the value of definitive local therapy for node-positive disease prior to 2012, and it is therefore still somewhat surprising that local therapy continued in a downward trajectory from 2004 to 2012 rather than slightly increasing or being stable. 7 Nevertheless, in the absence of prospective, randomized data evaluating the use of local therapy for metastatic disease, practice patterns have relied heavily on previous recommendations. Several ongoing trials will inform future changes in practice patterns. Notably, the STAMPEDE trial (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy, NCT00268476) and the HORRAD trial (ISRCTN 06890529) will compare ADT alone to ADT with radiation. PEACE1 (NCT01957436) will compare ADT ± RT ± abiraterone acetate with prednisone ± docetaxxel. Finally, study NCT01751438 will compare systemic therapy combined with radiation or surgery to systemic therapy alone. Changes in practice patterns in light of these ongoing results ought to be compared to previous practice patterns to better understand the changes in outcomes for patients with metastatic prostate cancer. Another possible explanation is that the years 2004 to 2012 were particularly exciting in terms of the development of new systemic therapies for metastatic prostate cancer. Starting with survival improvements from docetaxel in 2004 to the advent of abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223 after 2008, the large number of new systemic therapies for metastatic disease may have led physicians to use local therapy less for metastatic disease. However, as none of these therapies is permanently curative and as there is emerging retrospective data on the potential value of definitive therapy in metastatic disease, we may start to see this trend abate in future studies after 2012. Additional randomized controlled trials may elucidate the utility of radiation and surgery of the primary site. Accordingly, an additional arm was added to the STAMPEDE trial, which will investigate the role of RT in metastatic disease. 23 Originally published in 1996, the National Comprehensive Cancer Network guidelines recommend ADT as the primary treatment modality for metastatic prostate cancer. Oligometastatic disease, in particular, is treated with ADT alone per guidelines. Our findings suggest that conformation to the National Comprehensive Cancer Network guidelines was increasing in both academic and nonacademic settings over this period, as the use of ADT for metastatic disease increased from 70.2% in 2004 compared to 77.9% in 2012.
In light of these emerging data, the decreasing trend in use of locoregional treatment may change. The practice patterns illustrated in 2004e2012 may be contrasted to future trends as the paradigm shifts. Changes in the outcomes of patients with metastatic disease ought to be interpreted in light of the evolving practice patterns illustrated here (Table 3 ). In addition, as the frequency of screening for prostate cancer changes, more patients may present with advanced disease. Understanding the treatment of these complex patients will become increasingly important.
This study has certain limitations. As discussed, because our dataset was limited to patients diagnosed between 2004 and 2012, more recent trends could not be observed. In addition, owing to the retrospective nature of the study, confounding factors may exist that were not accounted for. Importantly, because detailed data regarding metastatic number and sites for patients were not available, this information could not be factored into treatment consideration. Finally, because of the data available in the NCDB, we were unable to differentiate between trends in treatment for oligometastatic versus widely metastatic disease. We attempted to address this limitation using subgroup analysis based on PSA score, but no differences were found.
Conclusion
The use of definitive local treatment for metastatic prostate cancer decreased from 2004 to 2012, possibly because of advances in systemic therapy during this time. Given the recent accumulating evidence on the value of local therapy in improving outcomes for these patients, these trends may reverse in the future; however, prospective randomized trials are needed to clarify the exact benefit.
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